Skip to Main Content

Advertisement

Skip Nav Destination

Season 2, Episode 8

In this week’s episode, we will learn about the cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura, review outcomes of a phase 2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease, and examine results of a phase 1/2 study looking at the use of ibrutinib and obinutuzimab plus venetoclax in patients with mantle-cell lymphoma.

Released February 25, 2021

The articles highlighted in this episode are listed below:


Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X